ImmunityBio, Inc. — Director's Dealing 2023

Feb 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2023-02-05

Reporting Person: Adcock Richard (Director, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-05	Common Stock	M	83333	—	Acquired	227774	Direct
2023-02-05	Common Stock	F	42192	$4.33	Disposed	185582	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-05	Restricted Stock Units	$	M	83333	Disposed		Common Stock (83333.0)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2: On February 5, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 3, 2022 was the settlement price used to calculate the shares withheld.

F3: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 83,333 of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 83,334 of the shares shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 5, 2021.